{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:37:11Z","timestamp":1794652631693,"version":"4.9.1"},"reference-count":219,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01192-w","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T18:28:34Z","timestamp":1767637714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of Immune Responses Against AAV Encoded Transgene Products"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9405-7718","authenticated-orcid":false,"given":"Boris","family":"Gorovits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0686-4581","authenticated-orcid":false,"given":"Mitra","family":"Azadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-9948","authenticated-orcid":false,"given":"Michele","family":"Fiscella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0722-6101","authenticated-orcid":false,"given":"Travis","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7796-7770","authenticated-orcid":false,"given":"Magdalena","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9758-2186","authenticated-orcid":false,"given":"Sylvia","family":"Janetzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7019-729X","authenticated-orcid":false,"given":"Vibha","family":"Jawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1350-0293","authenticated-orcid":false,"given":"Brian","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2772-5154","authenticated-orcid":false,"given":"Yanmei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2727-9887","authenticated-orcid":false,"given":"Yolanda D.","family":"Mahnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0856-3313","authenticated-orcid":false,"given":"Mauricio","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-0187","authenticated-orcid":false,"given":"Ritankar","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-8820","authenticated-orcid":false,"given":"Michelle","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0972-0908","authenticated-orcid":false,"given":"Mark","family":"Milton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9144-1182","authenticated-orcid":false,"given":"Robert","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-8473","authenticated-orcid":false,"given":"Michael A.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-5784","authenticated-orcid":false,"given":"Saleem","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3480-0894","authenticated-orcid":false,"given":"Veerle","family":"Snoeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3794-6441","authenticated-orcid":false,"given":"Christian","family":"Vettermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3606-4420","authenticated-orcid":false,"given":"Bonnie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9881-2443","authenticated-orcid":false,"given":"An","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"3","key":"1192_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2174\/1566523054065039","volume":"5","author":"AK Zaiss","year":"2005","unstructured":"Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther. 2005;5(3):323\u201331.","journal-title":"Curr Gene Ther"},{"issue":"3","key":"1192_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"H Costa Verdera","year":"2020","unstructured":"Costa Verdera H, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28(3):723\u201346.","journal-title":"Mol Ther"},{"issue":"11","key":"1192_CR3","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.94.11.5804","volume":"94","author":"RW Herzog","year":"1997","unstructured":"Herzog RW, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A. 1997;94(11):5804\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10045","key":"1192_CR4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","volume":"388","author":"J Bennett","year":"2016","unstructured":"Bennett J, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388(10045):661\u201372.","journal-title":"Lancet"},{"issue":"13","key":"1192_CR5","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","volume":"119","author":"G Buchlis","year":"2012","unstructured":"Buchlis G, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood. 2012;119(13):3038\u201341.","journal-title":"Blood"},{"issue":"6","key":"1192_CR6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ymthe.2017.03.029","volume":"25","author":"C Mueller","year":"2017","unstructured":"Mueller C, et al. 5 year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency. Mol Ther. 2017;25(6):1387\u201394.","journal-title":"Mol Ther"},{"issue":"21","key":"1192_CR7","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994\u20132004.","journal-title":"N Engl J Med"},{"issue":"4","key":"1192_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","volume":"21","author":"S Daya","year":"2008","unstructured":"Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21(4):583\u201393.","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"1192_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1089\/hum.2016.160","volume":"27","author":"LM Kattenhorn","year":"2016","unstructured":"Kattenhorn LM, et al. Adeno-associated virus gene therapy for liver disease. Hum Gene Ther. 2016;27(12):947\u201361.","journal-title":"Hum Gene Ther"},{"key":"1192_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107453","volume":"207","author":"NF Nidetz","year":"2020","unstructured":"Nidetz NF, et al. Adeno-associated viral vector-mediated immune responses: understanding barriers to gene delivery. Pharmacol Ther. 2020;207:107453.","journal-title":"Pharmacol Ther"},{"key":"1192_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.05.006","volume":"342","author":"RW Herzog","year":"2019","unstructured":"Herzog RW. Complexity of immune responses to AAV transgene products - example of factor IX. Cell Immunol. 2019;342:103658.","journal-title":"Cell Immunol"},{"issue":"12","key":"1192_CR12","first-page":"3958","volume":"117","author":"SW Lin","year":"2007","unstructured":"Lin SW, et al. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest. 2007;117(12):3958\u201370.","journal-title":"J Clin Invest"},{"key":"1192_CR13","doi-asserted-by":"publisher","first-page":"753467","DOI":"10.3389\/fimmu.2021.753467","volume":"12","author":"K Rapti","year":"2021","unstructured":"Rapti K, Grimm D. Adeno-associated viruses (AAV) and host immunity - a race between the hare and the hedgehog. Front Immunol. 2021;12:753467.","journal-title":"Front Immunol"},{"issue":"3","key":"1192_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/mt.2011.280","volume":"20","author":"T Wu","year":"2012","unstructured":"Wu T, et al. Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther. 2012;20(3):572\u20139.","journal-title":"Mol Ther"},{"issue":"1\u20132","key":"1192_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cellimm.2008.01.005","volume":"250","author":"J Millar","year":"2007","unstructured":"Millar J, et al. The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector. Cell Immunol. 2007;250(1\u20132):55\u201367.","journal-title":"Cell Immunol"},{"issue":"5","key":"1192_CR16","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1128\/JVI.72.5.4212-4223.1998","volume":"72","author":"K Jooss","year":"1998","unstructured":"Jooss K, et al. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol. 1998;72(5):4212\u201323.","journal-title":"J Virol"},{"issue":"5","key":"1192_CR17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","volume":"108","author":"R Dingman","year":"2019","unstructured":"Dingman R, Balu-Iyer SV. Immunogenicity of protein pharmaceuticals. J Pharm Sci. 2019;108(5):1637\u201354.","journal-title":"J Pharm Sci"},{"issue":"22","key":"1192_CR18","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","volume":"1","author":"M Shima","year":"2017","unstructured":"Shima M, et al. Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1(22):1891\u20139.","journal-title":"Blood Adv"},{"issue":"9","key":"1192_CR19","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","volume":"28","author":"RL West","year":"2008","unstructured":"West RL, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn\u2019s disease. Aliment Pharmacol Ther. 2008;28(9):1122\u20136.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 8","key":"1192_CR20","first-page":"viii37","volume":"18","author":"N Casadevall","year":"2003","unstructured":"Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant. 2003;18(Suppl 8):viii37-41.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 5","key":"1192_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/17.suppl_5.42","volume":"17","author":"N Casadevall","year":"2002","unstructured":"Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant. 2002;17(Suppl 5):42\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"15","key":"1192_CR22","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell JR, et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N Engl J Med. 2010;363(15):1429\u201337.","journal-title":"N Engl J Med"},{"issue":"2","key":"1192_CR23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29(2):464\u201388.","journal-title":"Mol Ther"},{"key":"1192_CR24","first-page":"471","volume":"26","author":"TY Yang","year":"2022","unstructured":"Yang TY, et al. Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper. Mol Ther. 2022;26:471\u201394.","journal-title":"Mol Ther"},{"issue":"3","key":"1192_CR25","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00814-5","volume":"25","author":"B Gorovits","year":"2023","unstructured":"Gorovits B, et al. Evaluation of cellular immune response to adeno-associated virus-based gene therapy. AAPS J. 2023;25(3):47.","journal-title":"AAPS J"},{"issue":"6","key":"1192_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1208\/s12248-021-00628-3","volume":"23","author":"B Gorovits","year":"2021","unstructured":"Gorovits B, et al. Evaluation of the humoral response to adeno-associated virus-based gene therapy modalities using total antibody assays. AAPS J. 2021;23(6):108.","journal-title":"AAPS J"},{"issue":"2","key":"1192_CR27","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0403-1","volume":"22","author":"B Gorovits","year":"2020","unstructured":"Gorovits B, et al. Recommendations for the development of cell-based anti-viral vector neutralizing antibody assays. AAPS J. 2020;22(2):24.","journal-title":"AAPS J"},{"issue":"3","key":"1192_CR28","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00796-4","volume":"25","author":"JR Mora","year":"2023","unstructured":"Mora JR, Richards SM. The AAPS journal theme issue: compendium of immunogenicity risk assessments: an industry guidance built on experience and published work. AAPS J. 2023;25(3):43.","journal-title":"AAPS J"},{"issue":"1\u20132","key":"1192_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2008.01.001","volume":"333","author":"E Koren","year":"2008","unstructured":"Koren E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333(1\u20132):1\u20139.","journal-title":"J Immunol Methods"},{"key":"1192_CR30","unstructured":"FDA. Immunogenicity Assessment for Therapeutic Protein Products. 2014 [cited 2025 May 08]; Available from: https:\/\/www.fda.gov\/media\/85017\/download. Accessed\u00a003 Dec 2025."},{"issue":"2","key":"1192_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/cei.12742","volume":"184","author":"GR Gunn","year":"2016","unstructured":"Gunn GR, et al. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clin Exp Immunol. 2016;184(2):137\u201346.","journal-title":"Clin Exp Immunol"},{"key":"1192_CR32","first-page":"23","volume":"112","author":"H Schellekens","year":"2003","unstructured":"Schellekens H, Casadevall N. Immunogenicity of biopharmaceuticals. The European perspective. Dev Biol (Basel). 2003;112:23\u20138.","journal-title":"Dev Biol (Basel)"},{"issue":"11","key":"1192_CR33","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/S0149-2918(02)80075-3","volume":"24","author":"H Schellekens","year":"2002","unstructured":"Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24(11):1720\u201340.","journal-title":"Clin Ther"},{"issue":"5","key":"1192_CR34","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G Shankar","year":"2008","unstructured":"Shankar G, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267\u201381.","journal-title":"J Pharm Biomed Anal"},{"key":"1192_CR35","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","volume":"31","author":"JS Blum","year":"2013","unstructured":"Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443\u201373.","journal-title":"Annu Rev Immunol"},{"key":"1192_CR36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.iy.13.040195.003103","volume":"13","author":"DR Madden","year":"1995","unstructured":"Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol. 1995;13:587\u2013622.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"1192_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nri3818","volume":"15","author":"PA Roche","year":"2015","unstructured":"Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol. 2015;15(4):203\u201316.","journal-title":"Nat Rev Immunol"},{"key":"1192_CR38","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3389\/fimmu.2020.01276","volume":"11","author":"EM Muntjewerff","year":"2020","unstructured":"Muntjewerff EM, Meesters LD, van den Bogaart G. Antigen cross-presentation by macrophages. Front Immunol. 2020;11:1276.","journal-title":"Front Immunol"},{"issue":"13","key":"1192_CR39","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1128\/JVI.00278-09","volume":"83","author":"C Li","year":"2009","unstructured":"Li C, et al. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. J Virol. 2009;83(13):6817\u201324.","journal-title":"J Virol"},{"key":"1192_CR40","unstructured":"FDA. Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics Guidance for Industry 2024 [cited 2025 May 08]; Available from: https:\/\/www.fda.gov\/media\/159414\/download. Accessed\u00a003 Dec 2025."},{"issue":"12","key":"1192_CR41","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41573-024-01051-x","volume":"23","author":"PJ Carter","year":"2024","unstructured":"Carter PJ, Quarmby V. Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics. Nat Rev Drug Discov. 2024;23(12):898\u2013913.","journal-title":"Nat Rev Drug Discov"},{"key":"1192_CR42","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3389\/fimmu.2020.01301","volume":"11","author":"V Jawa","year":"2020","unstructured":"Jawa V, et al. T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation-updated consensus and review 2020. Front Immunol. 2020;11:1301.","journal-title":"Front Immunol"},{"issue":"1","key":"1192_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ajmg.c.31319","volume":"160c","author":"DS Bali","year":"2012","unstructured":"Bali DS, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012;160c(1):40\u20139.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"1192_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111542","author":"LA Martinez Velazquez","year":"2021","unstructured":"Martinez Velazquez LA, Ballios BG. The next generation of molecular and cellular therapeutics for inherited retinal disease. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222111542.","journal-title":"Int J Mol Sci"},{"key":"1192_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119523","volume":"585","author":"NB Pham","year":"2020","unstructured":"Pham NB, Meng WS. Protein aggregation and immunogenicity of biotherapeutics. Int J Pharm. 2020;585:119523.","journal-title":"Int J Pharm"},{"issue":"6","key":"1192_CR46","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1007\/s11095-011-0621-4","volume":"29","author":"A Seidl","year":"2012","unstructured":"Seidl A, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29(6):1454\u201367.","journal-title":"Pharm Res"},{"key":"1192_CR47","doi-asserted-by":"publisher","first-page":"675897","DOI":"10.3389\/fimmu.2021.675897","volume":"12","author":"BA Hamilton","year":"2021","unstructured":"Hamilton BA, Wright JF. Challenges posed by immune responses to AAV vectors: addressing root causes. Front Immunol. 2021;12:675897.","journal-title":"Front Immunol"},{"issue":"8","key":"1192_CR48","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/14728222.2010.501333","volume":"14","author":"X Huang","year":"2010","unstructured":"Huang X, Yang Y. Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses. Expert Opin Ther Targets. 2010;14(8):787\u201396.","journal-title":"Expert Opin Ther Targets"},{"key":"1192_CR49","doi-asserted-by":"publisher","first-page":"104823","DOI":"10.1016\/j.cellimm.2024.104823","volume":"399\u2013400","author":"JD Glenn","year":"2024","unstructured":"Glenn JD, et al. The presence of CpGs in AAV gene therapy vectors induces a plasmacytoid dendritic cell-like population very early after administration. Cell Immunol. 2024;399\u2013400:104823.","journal-title":"Cell Immunol"},{"issue":"4","key":"1192_CR50","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/erv.10.174","volume":"10","author":"C Bode","year":"2011","unstructured":"Bode C, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10(4):499\u2013511.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"1192_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40259-017-0255-0","volume":"32","author":"JC Chapin","year":"2018","unstructured":"Chapin JC, Monahan PE. Gene therapy for hemophilia: progress to date. BioDrugs. 2018;32(1):9\u201325.","journal-title":"BioDrugs"},{"issue":"3","key":"1192_CR52","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","volume":"28","author":"JF Wright","year":"2020","unstructured":"Wright JF. Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare? Mol Ther. 2020;28(3):701\u20133.","journal-title":"Mol Ther"},{"key":"1192_CR53","doi-asserted-by":"publisher","DOI":"10.1155\/jimr\/5006201","volume":"2025","author":"L Han","year":"2025","unstructured":"Han L, et al. Immune tolerance regulation is critical to immune homeostasis. J Immunol Res. 2025;2025:5006201.","journal-title":"J Immunol Res"},{"issue":"4","key":"1192_CR54","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10545-017-0053-3","volume":"40","author":"J Baruteau","year":"2017","unstructured":"Baruteau J, et al. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. J Inherit Metab Dis. 2017;40(4):497\u2013517.","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"1192_CR55","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1016\/j.jtha.2024.07.012","volume":"22","author":"P Batty","year":"2024","unstructured":"Batty P, Lillicrap D. Adeno-associated viral vector integration: implications for long-term efficacy and safety. J Thromb Haemost. 2024;22(11):2945\u201360.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1192_CR56","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/gim.2015.57","volume":"17","author":"KL Berrier","year":"2015","unstructured":"Berrier KL, et al. CORRIGENDUM: CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med. 2015;17(7):596.","journal-title":"Genet Med"},{"issue":"7","key":"1192_CR57","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/jth.12958","volume":"13","author":"AC Goodeve","year":"2015","unstructured":"Goodeve AC. Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost. 2015;13(7):1184\u201395.","journal-title":"J Thromb Haemost"},{"key":"1192_CR58","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94328","author":"ZB Kazi","year":"2017","unstructured":"Kazi ZB, et al. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight. 2017. https:\/\/doi.org\/10.1172\/jci.insight.94328.","journal-title":"JCI Insight"},{"issue":"10","key":"1192_CR59","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/mt.2009.159","volume":"17","author":"O Cao","year":"2009","unstructured":"Cao O, et al. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther. 2009;17(10):1733\u201342.","journal-title":"Mol Ther"},{"issue":"26","key":"1192_CR60","doi-asserted-by":"publisher","first-page":"10770","DOI":"10.1073\/pnas.0902269106","volume":"106","author":"C Li","year":"2009","unstructured":"Li C, et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci U S A. 2009;106(26):10770\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1192_CR61","first-page":"191","volume":"11","author":"JA Greig","year":"2018","unstructured":"Greig JA, et al. AAV8 gene therapy for Crigler-Najjar syndrome in macaques elicited transgene T cell responses that are resident to the liver. Mol Ther. 2018;11:191\u2013201.","journal-title":"Mol Ther"},{"key":"1192_CR62","volume":"3","author":"PA Doerfler","year":"2016","unstructured":"Doerfler PA, et al. Targeted approaches to induce immune tolerance for Pompe disease therapy. Mol Ther. 2016;3:15053.","journal-title":"Mol Ther"},{"issue":"1","key":"1192_CR63","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26\u201333.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1192_CR64","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ymthe.2024.03.016","volume":"32","author":"R Kaczmarek","year":"2024","unstructured":"Kaczmarek R, Samelson-Jones BJ, Herzog RW. Immune tolerance induction by hepatic gene transfer: first-in-human evidence. Mol Ther. 2024;32(4):863\u20134.","journal-title":"Mol Ther"},{"issue":"2","key":"1192_CR65","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1208\/s12248-016-9878-1","volume":"18","author":"B Gorovits","year":"2016","unstructured":"Gorovits B, et al. Pre-existing antibody: biotherapeutic modality-based review. AAPS J. 2016;18(2):311\u201320.","journal-title":"AAPS J"},{"issue":"Suppl 2","key":"1192_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-018-0562-1","volume":"44","author":"D Concolino","year":"2018","unstructured":"Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44(Suppl 2):120.","journal-title":"Ital J Pediatr"},{"issue":"3","key":"1192_CR67","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","volume":"105","author":"WR Wilcox","year":"2012","unstructured":"Wilcox WR, et al. Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. Mol Genet Metab. 2012;105(3):443\u20139.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"1192_CR68","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.clinthera.2016.11.017","volume":"39","author":"B Long","year":"2017","unstructured":"Long B, et al. Long-term immunogenicity of Elosulfase alfa in the treatment of Morquio A syndrome: results from MOR-005, a phase III extension study. Clin Ther. 2017;39(1):118-129.e3.","journal-title":"Clin Ther"},{"issue":"9","key":"1192_CR69","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Brand E. Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. J Am Soc Nephrol. 2018;29(9):2265\u201378.","journal-title":"J Am Soc Nephrol"},{"issue":"17","key":"1192_CR70","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s40265-021-01621-y","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease. Drugs. 2021;81(17):1969\u201381.","journal-title":"Drugs"},{"issue":"13","key":"1192_CR71","doi-asserted-by":"publisher","first-page":"285","DOI":"10.21037\/atm.2019.05.27","volume":"7","author":"AK Desai","year":"2019","unstructured":"Desai AK, et al. Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review. Ann Transl Med. 2019;7(13):285.","journal-title":"Ann Transl Med"},{"key":"1192_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/biom13091414","author":"IAM Ditters","year":"2023","unstructured":"Ditters IAM, et al. Are anti-rhGAA antibodies a determinant of treatment outcome in adults with late-onset Pompe disease? A systematic review. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13091414.","journal-title":"Biomolecules"},{"issue":"8","key":"1192_CR73","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria SG, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13(8):729\u201336.","journal-title":"Genet Med"},{"issue":"1","key":"1192_CR74","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/2040620712464509","volume":"4","author":"C Witmer","year":"2013","unstructured":"Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59\u201372.","journal-title":"Ther Adv Hematol"},{"key":"1192_CR75","unstructured":"ClinicalTrials.gov. Safety, tolerability, and efficacy study of valoctocogene roxaparvovec in hemophilia a with active or prior inhibitors (GENEr8-INH). NCT04684940. cited 2025 May 08. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04684940?term=NCT04684940&rank=1. Accessed\u00a003 Dec 2025."},{"issue":"S1","key":"1192_CR76","first-page":"18","volume":"30","author":"G Young","year":"2024","unstructured":"Young G, et al. Safety and efficacy of valoctocogene roxaparvovec inparticipants with active and prior FVIII inhibitors: Preliminary results from GENEr8-INH, a phase 1\/2 study. Main Congress Oral Abstracts Haemophilia. 2024;30(S1):18\u201327.","journal-title":"Main Congress Oral Abstracts Haemophilia"},{"key":"1192_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.07.035","volume":"33","author":"S Khan","year":"2023","unstructured":"Khan S, et al. P54 T-cell response to SRP-9001 dystrophin transgene in a patient treated with delandistrogene moxeparvovec: a case of immune-mediated myositis. Neuromuscul Disord. 2023;33:S72.","journal-title":"Neuromuscul Disord"},{"key":"1192_CR78","unstructured":"FDA. ELEVIDYS Highlights of Prescribing Information. 2023 [cited 2025 Oct 9]; Available from: https:\/\/www.fda.gov\/media\/184855\/download?attachment. Accessed\u00a003 Dec 2025."},{"issue":"1821","key":"1192_CR79","volume":"282","author":"AK Simon","year":"2015","unstructured":"Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282(1821):20143085.","journal-title":"Proc Biol Sci"},{"issue":"1","key":"1192_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000654","volume":"4","author":"E Gong","year":"2025","unstructured":"Gong E, et al. Immunotherapy response in immunosuppressed patients with Merkel cell carcinoma: analysis of 183 patients. BMJ Oncol. 2025;4(1):e000654.","journal-title":"BMJ Oncol"},{"key":"1192_CR81","first-page":"83","volume":"15","author":"J Poupiot","year":"2019","unstructured":"Poupiot J, et al. Role of regulatory T cell and effector T cell exhaustion in liver-mediated transgene tolerance in muscle. Mol Ther. 2019;15:83\u2013100.","journal-title":"Mol Ther"},{"issue":"7","key":"1192_CR82","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","volume":"110","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood. 2007;110(7):2334\u201341.","journal-title":"Blood"},{"issue":"5","key":"1192_CR83","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2174\/156652307782151425","volume":"7","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther. 2007;7(5):316\u201324.","journal-title":"Curr Gene Ther"},{"issue":"1","key":"1192_CR84","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood-2003-05-1446","volume":"103","author":"VR Arruda","year":"2004","unstructured":"Arruda VR, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood. 2004;103(1):85\u201392.","journal-title":"Blood"},{"issue":"4","key":"1192_CR85","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2174\/1566523215666150630121750","volume":"15","author":"F Boisgerault","year":"2015","unstructured":"Boisgerault F, Mingozzi F. The skeletal muscle environment and its role in immunity and tolerance to AAV vector-mediated gene transfer. Curr Gene Ther. 2015;15(4):381\u201394.","journal-title":"Curr Gene Ther"},{"issue":"9","key":"1192_CR86","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1172\/JCI200316887","volume":"111","author":"F Mingozzi","year":"2003","unstructured":"Mingozzi F, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest. 2003;111(9):1347\u201356.","journal-title":"J Clin Invest"},{"key":"1192_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.12.002","volume":"342","author":"GD Keeler","year":"2019","unstructured":"Keeler GD, Markusic DM, Hoffman BE. Liver induced transgene tolerance with AAV vectors. Cell Immunol. 2019;342:103728.","journal-title":"Cell Immunol"},{"issue":"3","key":"1192_CR88","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ymthe.2006.05.004","volume":"14","author":"H Jiang","year":"2006","unstructured":"Jiang H, et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther. 2006;14(3):452\u20135.","journal-title":"Mol Ther"},{"issue":"22","key":"1192_CR89","doi-asserted-by":"publisher","first-page":"11605","DOI":"10.1128\/JVI.76.22.11605-11611.2002","volume":"76","author":"D Favre","year":"2002","unstructured":"Favre D, et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol. 2002;76(22):11605\u201311.","journal-title":"J Virol"},{"issue":"1","key":"1192_CR90","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/mt.2009.251","volume":"18","author":"A Toromanoff","year":"2010","unstructured":"Toromanoff A, et al. Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther. 2010;18(1):151\u201360.","journal-title":"Mol Ther"},{"key":"1192_CR91","volume":"2","author":"DJ Hui","year":"2015","unstructured":"Hui DJ, et al. AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes. Mol Ther. 2015;2:15029.","journal-title":"Mol Ther"},{"issue":"1","key":"1192_CR92","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","volume":"9","author":"A Meliani","year":"2018","unstructured":"Meliani A, et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun. 2018;9(1):4098.","journal-title":"Nat Commun"},{"issue":"1","key":"1192_CR93","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.0105-2896.2009.00873.x","volume":"234","author":"JV Forrester","year":"2010","unstructured":"Forrester JV, et al. Dendritic cell physiology and function in the eye. Immunol Rev. 2010;234(1):282\u2013304.","journal-title":"Immunol Rev"},{"key":"1192_CR94","unstructured":"FDA. LUXTURNA (voretigene neparvovec-rzyl) Prescribing Information. 2017 [cited 2025 May 9]; Available from: https:\/\/www.fda.gov\/media\/109906\/download. Accessed\u00a003 Dec 2025."},{"issue":"120","key":"1192_CR95","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002865","volume":"4","author":"J Bennett","year":"2012","unstructured":"Bennett J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012;4(120):120ra15.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1192_CR96","doi-asserted-by":"publisher","first-page":"e00435","DOI":"10.1016\/j.neurot.2024.e00435","volume":"21","author":"AL Harkins","year":"2024","unstructured":"Harkins AL, Ambegaokar PP, Keeler AM. Immune responses to central nervous system directed adeno-associated virus gene therapy: does direct CNS delivery make a difference? Neurotherapeutics. 2024;21(4):e00435.","journal-title":"Neurotherapeutics"},{"key":"1192_CR97","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","volume":"35","author":"M Colonna","year":"2017","unstructured":"Colonna M, Butovsky O. Microglia function in the central nervous System during health and neurodegeneration. Annu Rev Immunol. 2017;35:441\u201368.","journal-title":"Annu Rev Immunol"},{"key":"1192_CR98","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3389\/fimmu.2021.655478","volume":"12","author":"ML Gougeon","year":"2021","unstructured":"Gougeon ML, et al. Cell-mediated immunity to NAGLU transgene following intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome. Front Immunol. 2021;12:2021.","journal-title":"Front Immunol"},{"issue":"2","key":"1192_CR99","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/brain\/awy331","volume":"142","author":"K Kojima","year":"2019","unstructured":"Kojima K, et al. Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency. Brain. 2019;142(2):322\u201333.","journal-title":"Brain"},{"issue":"10","key":"1192_CR100","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","volume":"32","author":"B Vrellaku","year":"2024","unstructured":"Vrellaku B, et al. A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders. Mol Ther. 2024;32(10):3220\u201359.","journal-title":"Mol Ther"},{"issue":"10097","key":"1192_CR101","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849\u201360.","journal-title":"Lancet"},{"issue":"18","key":"1192_CR102","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"1192_CR103","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2\u201313.","journal-title":"Mol Cell Endocrinol"},{"issue":"10436","key":"1192_CR104","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","volume":"403","author":"PA Campochiaro","year":"2024","unstructured":"Campochiaro PA, et al. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study. Lancet. 2024;403(10436):1563\u201373.","journal-title":"Lancet"},{"issue":"7","key":"1192_CR105","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.ymthe.2024.05.033","volume":"32","author":"BR Long","year":"2024","unstructured":"Long BR, et al. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A. Mol Ther. 2024;32(7):2052\u201363.","journal-title":"Mol Ther"},{"key":"1192_CR106","first-page":"85","volume":"12","author":"P Colella","year":"2019","unstructured":"Colella P, et al. AAV gene transfer with tandem promoter design prevents anti-transgene immunity and provides persistent efficacy in neonate Pompe mice. Mol Ther. 2019;12:85\u2013101.","journal-title":"Mol Ther"},{"issue":"5","key":"1192_CR107","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","volume":"12","author":"LM Franco","year":"2005","unstructured":"Franco LM, et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther. 2005;12(5):876\u201384.","journal-title":"Mol Ther"},{"issue":"5","key":"1192_CR108","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1089\/hum.2011.063","volume":"23","author":"P Zhang","year":"2012","unstructured":"Zhang P, et al. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine Pompe disease. Hum Gene Ther. 2012;23(5):460\u201372.","journal-title":"Hum Gene Ther"},{"key":"1192_CR109","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam6375","author":"F Puzzo","year":"2017","unstructured":"Puzzo F, et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aam6375.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1192_CR110","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/hum.2014.115","volume":"26","author":"SO Han","year":"2015","unstructured":"Han SO, et al. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. Hum Gene Ther. 2015;26(1):26\u201335.","journal-title":"Hum Gene Ther"},{"key":"1192_CR111","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3389\/fimmu.2020.00618","volume":"11","author":"BJ Samelson-Jones","year":"2020","unstructured":"Samelson-Jones BJ, Arruda VR. Translational potential of immune tolerance induction by AAV liver-directed factor VIII gene therapy for hemophilia A. Front Immunol. 2020;11:618.","journal-title":"Front Immunol"},{"issue":"6","key":"1192_CR112","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/jth.13331","volume":"14","author":"VR Arruda","year":"2016","unstructured":"Arruda VR, Samelson-Jones BJ. Gene therapy for immune tolerance induction in hemophilia with inhibitors. J Thromb Haemost. 2016;14(6):1121\u201334.","journal-title":"J Thromb Haemost"},{"key":"1192_CR113","volume":"1","author":"BK Sack","year":"2014","unstructured":"Sack BK, et al. Development of gene transfer for induction of antigen-specific tolerance. Mol Ther. 2014;1:14013.","journal-title":"Mol Ther"},{"issue":"25","key":"1192_CR114","doi-asserted-by":"publisher","first-page":"E2540","DOI":"10.1073\/pnas.1406674111","volume":"111","author":"SS Tay","year":"2014","unstructured":"Tay SS, et al. Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses. Proc Natl Acad Sci USA. 2014;111(25):E2540-9.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1192_CR115","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ppul.25055","volume":"56","author":"NJ Abreu","year":"2021","unstructured":"Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol. 2021;56(4):710\u201320.","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"1192_CR116","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1177\/1060028020914274","volume":"54","author":"D Stevens","year":"2020","unstructured":"Stevens D, et al. Onasemnogene abeparvovec-xioi: gene therapy for spinal muscular atrophy. Ann Pharmacother. 2020;54(10):1001\u20139.","journal-title":"Ann Pharmacother"},{"key":"1192_CR117","unstructured":"ClinicalTrials.gov. Study to evaluate the safety and efficacy of PF-06939926 for the treatment of duchenne muscular dystrophy. NCT04281485. cited 2025 May 09. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04281485?term=NCT04281485&rank=1. Accessed\u00a003 Dec 2025."},{"key":"1192_CR118","unstructured":"ClinicalTrials.gov. A gene transfer therapy study to evaluate the safety of and expression from delandistrogene moxeparvovec (SRP-9001) in participants with duchenne muscular dystrophy (DMD) (ENDEAVOR). NCT04626674. cited 2025 May 09. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04626674?term=NCT04626674&rank=1. Accessed\u00a003 Dec 2025."},{"key":"#cr-split#-1192_CR119.1","unstructured":"clinicaltrialsregister.eu. Microdystrophin (GNT0004) Gene Therapy Clinical Trial in Duchenne Muscular Dystrophy. A phase I\/II\/III study with a dose determination part followed by an efficacy and safety evaluation, quadruple blind placebo-controlled part and then by a long term safety follow up part, in ambulant boys. 2020-002093-27. [cited 2025 May 09]"},{"key":"#cr-split#-1192_CR119.2","unstructured":"Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002093-27\/FR. Accessed\u00a003 Dec 2025."},{"issue":"24","key":"1192_CR120","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMc2212912","volume":"388","author":"CG B\u00f6nnemann","year":"2023","unstructured":"B\u00f6nnemann CG, et al. Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy. N Engl J Med. 2023;388(24):2294\u20136.","journal-title":"N Engl J Med"},{"issue":"11","key":"1192_CR121","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1122","volume":"12","author":"DC G\u00f3recki","year":"2022","unstructured":"G\u00f3recki DC. Dystrophin immunogenicity and requirement in myogenic cells: paradigm shift in gene therapy for DMD. Clin Transl Med. 2022;12(11):e1122.","journal-title":"Clin Transl Med"},{"issue":"4","key":"1192_CR122","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.4.3","volume":"10","author":"YK Chan","year":"2021","unstructured":"Chan YK, et al. Inflammation in viral vector-mediated ocular gene therapy: a review and report from a workshop hosted by the Foundation Fighting Blindness, 9\/2020. Transl Vis Sci Technol. 2021;10(4):3.","journal-title":"Transl Vis Sci Technol"},{"key":"1192_CR123","unstructured":"ClinicalTrials.gov. A clinical trial of retinal gene therapy for x-linked retinitis pigmentosa using BIIB112 (XIRIUS). NCT03116113. [cited 2025 May 09]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT03116113?term=NCT03116113&rank=1. Accessed\u00a003 Dec 2025."},{"issue":"4","key":"1192_CR124","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/brv.12718","volume":"96","author":"M Whitehead","year":"2021","unstructured":"Whitehead M, et al. Humoral immune responses to AAV gene therapy in the ocular compartment. Biol Rev Camb Philos Soc. 2021;96(4):1616\u201344.","journal-title":"Biol Rev Camb Philos Soc"},{"issue":"5","key":"1192_CR125","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1089\/hum.2016.128","volume":"28","author":"JA Greig","year":"2017","unstructured":"Greig JA, et al. Characterization of adeno-associated viral vector-mediated human factor VIII gene therapy in hemophilia A mice. Hum Gene Ther. 2017;28(5):392\u2013402.","journal-title":"Hum Gene Ther"},{"key":"1192_CR126","first-page":"57","volume":"9","author":"HC Brown","year":"2018","unstructured":"Brown HC, et al. Target-cell-directed bioengineering approaches for gene therapy of hemophilia A. Mol Ther. 2018;9:57\u201369.","journal-title":"Mol Ther"},{"issue":"8","key":"1192_CR127","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1182\/bloodadvances.2021006359","volume":"6","author":"TS Lundgren","year":"2022","unstructured":"Lundgren TS, et al. Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice. Blood Adv. 2022;6(8):2628\u201345.","journal-title":"Blood Adv"},{"issue":"1","key":"1192_CR128","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/mt.2010.250","volume":"19","author":"LE Mays","year":"2011","unstructured":"Mays LE, Wilson JM. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther. 2011;19(1):16\u201327.","journal-title":"Mol Ther"},{"issue":"16","key":"1192_CR129","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1089\/hum.1997.8.16-1891","volume":"8","author":"RO Snyder","year":"1997","unstructured":"Snyder RO, et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther. 1997;8(16):1891\u2013900.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"1192_CR130","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1089\/104303401750061267","volume":"12","author":"L Cordier","year":"2001","unstructured":"Cordier L, et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther. 2001;12(2):205\u201315.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"1192_CR131","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1006\/mthe.2002.0525","volume":"5","author":"V Anand","year":"2002","unstructured":"Anand V, et al. A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. Mol Ther. 2002;5(2):125\u201332.","journal-title":"Mol Ther"},{"issue":"24","key":"1192_CR132","doi-asserted-by":"publisher","first-page":"13800","DOI":"10.1128\/JVI.01708-12","volume":"86","author":"J Rybniker","year":"2012","unstructured":"Rybniker J, et al. Incorporation of antigens into viral capsids augments immunogenicity of adeno-associated virus vector-based vaccines. J Virol. 2012;86(24):13800\u20134.","journal-title":"J Virol"},{"issue":"12","key":"1192_CR133","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera J, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 2021;20(12):1012\u201326.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1192_CR134","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1016\/j.ymthe.2021.08.020","volume":"29","author":"AD Baik","year":"2021","unstructured":"Baik AD, et al. Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies. Mol Ther. 2021;29(12):3512\u201324.","journal-title":"Mol Ther"},{"issue":"8","key":"1192_CR135","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/nbt.1484","volume":"26","author":"J Wang","year":"2008","unstructured":"Wang J, et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol. 2008;26(8):901\u20138.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1192_CR136","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1083\/jcb.98.4.1170","volume":"98","author":"I Mellman","year":"1984","unstructured":"Mellman I, Plutner H. Internalization and degradation of macrophage Fc receptors bound to polyvalent immune complexes. J Cell Biol. 1984;98(4):1170\u20137.","journal-title":"J Cell Biol"},{"key":"1192_CR137","first-page":"292","volume":"24","author":"L Wang","year":"2022","unstructured":"Wang L, et al. Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression. Mol Ther. 2022;24:292\u2013305.","journal-title":"Mol Ther"},{"issue":"3","key":"1192_CR138","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1007\/s12035-019-01845-w","volume":"57","author":"M Naidoo","year":"2020","unstructured":"Naidoo M, Anthony K. Dystrophin Dp71 and the neuropathophysiology of Duchenne muscular dystrophy. Mol Neurobiol. 2020;57(3):1748\u201367.","journal-title":"Mol Neurobiol"},{"issue":"8","key":"1192_CR139","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med. 2023;388(8):694\u2013705.","journal-title":"N Engl J Med"},{"issue":"11","key":"1192_CR140","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013\u201325.","journal-title":"N Engl J Med"},{"key":"1192_CR141","unstructured":"ClinicalTrials.gov. Dose-ranging study of ST-920, an AAV2\/\u200b6 human alpha galactosidase a gene therapy in subjects with fabry disease (STAAR). NCT04046224. [cited 2025 May 10]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT04046224?term=NCT04046224&rank=1. Accessed\u00a003 Dec 2025."},{"issue":"1\u20132","key":"1192_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","volume":"289","author":"AR Mire-Sluis","year":"2004","unstructured":"Mire-Sluis AR, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1\u20132):1\u201316.","journal-title":"J Immunol Methods"},{"issue":"14","key":"1192_CR143","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1056\/NEJMoa040528","volume":"351","author":"CL Bennett","year":"2004","unstructured":"Bennett CL, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351(14):1403\u20138.","journal-title":"N Engl J Med"},{"issue":"17\u201318","key":"1192_CR144","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/17576180.2024.2376949","volume":"16","author":"J Goodman","year":"2024","unstructured":"Goodman J, et al. Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum. Bioanalysis. 2024;16(17\u201318):905\u201313.","journal-title":"Bioanalysis"},{"issue":"1","key":"1192_CR145","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-024-00993-9","volume":"27","author":"CH Lai","year":"2024","unstructured":"Lai CH, et al. Challenging the standard immunogenicity assessment approach: 1-tiered ADA testing strategy in clinical trials. AAPS J. 2024;27(1):11.","journal-title":"AAPS J"},{"key":"1192_CR146","unstructured":"EMA. Guideline on Immunogenicity assessment of therapeutic proteins. 2017 [cited 2025 May 09]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed\u00a003 Dec 2025."},{"key":"1192_CR147","unstructured":"FDA. Immunogenicity Testing of Therapeutic Protein Products \u2014Developing and Validating Assays for Anti-Drug Antibody Detection. 2019 [cited 2025 May 09]; Available from: https:\/\/www.fda.gov\/media\/119788\/download. Accessed\u00a003 Dec 2025."},{"key":"1192_CR148","unstructured":"FDA. Human Gene Therapy for Hemophilia. 2020 [cited 2025 May 09]; Available from: https:\/\/www.fda.gov\/media\/113799\/download. Accessed\u00a003 Dec 2025."},{"key":"1192_CR149","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092129","author":"D Hatlem","year":"2019","unstructured":"Hatlem D, et al. Catching a SPY: using the SpyCatcher-SpyTag and related systems for labeling and localizing bacterial proteins. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20092129.","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"1192_CR150","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jim.2007.07.004","volume":"327","author":"JS Bourdage","year":"2007","unstructured":"Bourdage JS, et al. An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods. 2007;327(1\u20132):10\u20137.","journal-title":"J Immunol Methods"},{"key":"1192_CR151","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jim.2015.08.002","volume":"426","author":"J Zoghbi","year":"2015","unstructured":"Zoghbi J, et al. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays. J Immunol Methods. 2015;426:62\u20139.","journal-title":"J Immunol Methods"},{"issue":"3","key":"1192_CR152","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.yrtph.2007.07.005","volume":"49","author":"HW Smith","year":"2007","unstructured":"Smith HW, Butterfield A, Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul Toxicol Pharmacol. 2007;49(3):230\u20137.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"5","key":"1192_CR153","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","volume":"26","author":"H Sonoda","year":"2018","unstructured":"Sonoda H, et al. A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol Ther. 2018;26(5):1366\u201374.","journal-title":"Mol Ther"},{"key":"1192_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-3690-9_1","volume":"2768","author":"S Janetzki","year":"2024","unstructured":"Janetzki S. Important considerations for ELISpot validation. Methods Mol Biol. 2024;2768:1\u201313.","journal-title":"Methods Mol Biol"},{"key":"1192_CR155","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-1-4939-8567-8_2","volume":"1808","author":"S Janetzki","year":"2018","unstructured":"Janetzki S. Mastering the computational challenges of Elispot plate evaluation. Methods Mol Biol. 2018;1808:9\u201330.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"1192_CR156","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00262-007-0380-6","volume":"57","author":"S Janetzki","year":"2008","unstructured":"Janetzki S, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC\/SVI). Cancer Immunol Immunother. 2008;57(3):303\u201315.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"1192_CR157","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/nprot.2015.068","volume":"10","author":"S Janetzki","year":"2015","unstructured":"Janetzki S, et al. Guidelines for the automated evaluation of Elispot assays. Nat Protoc. 2015;10(7):1098\u2013115.","journal-title":"Nat Protoc"},{"issue":"1","key":"1192_CR158","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/cyto.a.24244","volume":"99","author":"LS Price","year":"2021","unstructured":"Price LS, et al. Gating harmonization guidelines for intracellular cytokine staining validated in second international multiconsortia proficiency panel conducted by Cancer Immunotherapy Consortium (CIC\/CRI). Cytometry A. 2021;99(1):107\u201316.","journal-title":"Cytometry A"},{"issue":"10","key":"1192_CR159","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/eji.201970107","volume":"49","author":"A Cossarizza","year":"2019","unstructured":"Cossarizza A, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur J Immunol. 2019;49(10):1457\u2013973.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1192_CR160","doi-asserted-by":"publisher","first-page":"11567","DOI":"10.1038\/s41598-020-68468-3","volume":"10","author":"L Le Lann","year":"2020","unstructured":"Le Lann L, et al. Standardization procedure for flow cytometry data harmonization in prospective multicenter studies. Sci Rep. 2020;10(1):11567.","journal-title":"Sci Rep"},{"issue":"11","key":"1192_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2017.52","volume":"8","author":"L Westera","year":"2017","unstructured":"Westera L, et al. Centrally determined standardization of flow cytometry methods reduces interlaboratory variation in a prospective multicenter study. Clin Transl Gastroenterol. 2017;8(11):e126.","journal-title":"Clin Transl Gastroenterol"},{"key":"1192_CR162","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-0716-3690-9_3","volume":"2768","author":"K Schnatbaum","year":"2024","unstructured":"Schnatbaum K, et al. An overview of peptides and peptide pools for antigen-specific stimulation in T-cell assays. Methods Mol Biol. 2024;2768:29\u201350.","journal-title":"Methods Mol Biol"},{"key":"1192_CR163","first-page":"183","volume":"22","author":"KS Patton","year":"2021","unstructured":"Patton KS, et al. Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-\u03b3 ELISpot method. Mol Ther. 2021;22:183\u201395.","journal-title":"Mol Ther"},{"key":"1192_CR164","unstructured":"CLSI. CLSI I\/LA26-A2 Performance of Single Cell Immune Response Assays. [cited 2025 May 09]; Available from: https:\/\/clsi.org\/shop\/standards\/ila26\/. Accessed\u00a003 Dec 2025."},{"issue":"3","key":"1192_CR165","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/cyto.a.23904","volume":"97","author":"S Van Gassen","year":"2020","unstructured":"Van Gassen S, et al. Cytonorm: a normalization algorithm for cytometry data. Cytometry A. 2020;97(3):268\u201378.","journal-title":"Cytometry A"},{"issue":"2","key":"1192_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.657","volume":"3","author":"L Ferrer-Font","year":"2023","unstructured":"Ferrer-Font L, et al. Ensuring full spectrum flow cytometry data quality for high-dimensional data analysis. Curr Protoc. 2023;3(2):e657.","journal-title":"Curr Protoc"},{"key":"1192_CR167","unstructured":"FDA. KEBILIDI (eladocagene exuparvovec-tneq) suspension, for intraputaminal infusion. Prescribing Information 2024 [cited 2025 May 09]; Available from: https:\/\/www.fda.gov\/media\/183530\/download. Accessed\u00a003 Dec 2025."},{"issue":"2","key":"1192_CR168","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","volume":"29","author":"BR Long","year":"2021","unstructured":"Long BR, et al. Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A. Mol Ther. 2021;29(2):597\u2013610.","journal-title":"Mol Ther"},{"issue":"9","key":"1192_CR169","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","volume":"28","author":"LA George","year":"2020","unstructured":"George LA, et al. Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol Ther. 2020;28(9):2073\u201382.","journal-title":"Mol Ther"},{"issue":"22","key":"1192_CR170","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","volume":"4","author":"BM Reipert","year":"2020","unstructured":"Reipert BM, et al. The prospective Hemophilia Inhibitor PUP study reveals distinct antibody signatures prior to FVIII inhibitor development. Blood Adv. 2020;4(22):5785\u201396.","journal-title":"Blood Adv"},{"issue":"19","key":"1192_CR171","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1182\/bloodadvances.2023011847","volume":"8","author":"BJ Samelson-Jones","year":"2024","unstructured":"Samelson-Jones BJ, Small JC, George LA. Roctavian gene therapy for hemophilia A. Blood Adv. 2024;8(19):5179\u201389.","journal-title":"Blood Adv"},{"issue":"3","key":"1192_CR172","first-page":"e36197","volume":"15","author":"T Ogbonmide","year":"2023","unstructured":"Ogbonmide T, et al. Gene therapy for spinal muscular atrophy (SMA): a review of current challenges and safety considerations for onasemnogene abeparvovec (Zolgensma). Cureus. 2023;15(3):e36197.","journal-title":"Cureus"},{"key":"1192_CR173","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.nmd.2023.07.105","volume":"33","author":"J Mendell","year":"2023","unstructured":"Mendell J, et al. P223 long-term follow-up of onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy (SMA) type 1. Neuromuscul Disord. 2023;33:S91.","journal-title":"Neuromuscul Disord"},{"key":"1192_CR174","unstructured":"AusPAR. Zolgensma: Australian Public Assessment Report for Onasemnogene abeparvovec. 2021 [cited 2025 May 10]; Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-onasemnogene-abeparvovec-210406.pdf. Accessed\u00a003 Dec 2025."},{"key":"1192_CR175","unstructured":"FDA. Zolgensma (onasemnogene abeparvovec-xioi): Prescribing Information 2019 [cited 2025 May 10]; Available from: https:\/\/www.fda.gov\/media\/126109\/download. Accessed\u00a003 Dec 2025."},{"key":"1192_CR176","unstructured":"EMA. Zolgensma. onasemnogene abeparvovec. 2022 [cited 2025 May 10]; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma. Accessed\u00a003 Dec 2025."},{"key":"1192_CR177","unstructured":"PMDA. ZOLGENSMA Intravenous Infusion. Report on the Deliberation Results. . 2020 [cited 2025 May 20]; Available from: https:\/\/www.pmda.go.jp\/files\/000251180.pdf. Accessed\u00a003 Dec 2025."},{"issue":"2","key":"1192_CR178","doi-asserted-by":"publisher","first-page":"e210268","DOI":"10.1212\/WNL.0000000000210268","volume":"104","author":"HJ McMillan","year":"2025","unstructured":"McMillan HJ, et al. Safety and efficacy of IV onasemnogene abeparvovec for pediatric patients with spinal muscular atrophy: the phase 3b SMART study. Neurology. 2025;104(2):e210268.","journal-title":"Neurology"},{"key":"1192_CR179","unstructured":"ClinicalTrials.gov. Gene transfer clinical trial for spinal muscular atrophy type 1. NCT02122952. [cited 2025 May 10]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT02122952?term=NCT02122952&rank=1. Accessed\u00a003 Dec 2025."},{"key":"1192_CR180","unstructured":"ClinicalTrials.gov. Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies. NCT03837184. [cited 2025 May 10]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT03837184?term=NCT03306277%0ANCT03461289%0ANCT03837184%0ANCT03381729&rank=1. Accessed\u00a003 Dec 2025."},{"key":"1192_CR181","unstructured":"ClinicalTrials.gov. Single-dose gene replacement therapy clinical trial for participants with spinal muscular atrophy type 1 (STRIVE-EU). NCT03461289. [cited 2025 May 10]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT03461289?term=NCT03306277%0ANCT03461289%0ANCT03837184%0ANCT03381729&rank=2. Accessed\u00a003 Dec 2025."},{"key":"1192_CR182","unstructured":"ClinicalTrials.gov. Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy (STRONG). NCT03381729. [cited 2025 May 10]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT03381729?term=NCT03306277%0ANCT03461289%0ANCT03837184%0ANCT03381729&rank=3. Accessed\u00a003 Dec 2025."},{"key":"1192_CR183","unstructured":"clinicalTrials.gov. Gene replacement therapy clinical trial for participants with spinal muscular atrophy type 1 (STR1VE). NCT03306277. [cited 2025 May 10]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT03306277?term=NCT03306277%0ANCT03461289%0ANCT03837184%0ANCT03381729&rank=4. Accessed\u00a003 Dec 2025."},{"key":"1192_CR184","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137207","author":"M Aoun","year":"2021","unstructured":"Aoun M, et al. Inherited retinal diseases due to RPE65 variants: from genetic diagnostic management to therapy. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22137207.","journal-title":"Int J Mol Sci"},{"key":"1192_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108761","volume":"212","author":"R Lopez-Rodriguez","year":"2021","unstructured":"Lopez-Rodriguez R, et al. RPE65-related retinal dystrophy: mutational and phenotypic spectrum in 45 affected patients. Exp Eye Res. 2021;212:108761.","journal-title":"Exp Eye Res"},{"key":"1192_CR186","unstructured":"EMA. Luxturna. voretigene neparvovec. 2018 [cited 2025 May 20]; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/luxturna. Accessed\u00a003 Dec 2025."},{"issue":"20","key":"1192_CR187","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","volume":"372","author":"JW Bainbridge","year":"2015","unstructured":"Bainbridge JW, et al. Long-term effect of gene therapy on Leber\u2019s congenital amaurosis. N Engl J Med. 2015;372(20):1887\u201397.","journal-title":"N Engl J Med"},{"issue":"6","key":"1192_CR188","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ophtha.2012.11.048","volume":"120","author":"F Testa","year":"2013","unstructured":"Testa F, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology. 2013;120(6):1283\u201391.","journal-title":"Ophthalmology"},{"issue":"21","key":"1192_CR189","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire AM, et al. Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis. N Engl J Med. 2008;358(21):2240\u20138.","journal-title":"N Engl J Med"},{"key":"1192_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108862","volume":"271","author":"J Biber","year":"2025","unstructured":"Biber J, et al. Retina-directed gene therapy: achievements and remaining challenges. Pharmacol Ther. 2025;271:108862.","journal-title":"Pharmacol Ther"},{"key":"1192_CR191","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.2147\/OPTH.S364200","volume":"16","author":"HH Ghoraba","year":"2022","unstructured":"Ghoraba HH, et al. Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses. Clin Ophthalmol. 2022;16:1753\u201371.","journal-title":"Clin Ophthalmol"},{"key":"1192_CR192","doi-asserted-by":"crossref","unstructured":"Hughes, D., Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing Phase 1\/2 study (STAAR). Personal Communication. 2025: Sangamo Inc.","DOI":"10.1016\/j.ymgme.2024.108773"},{"key":"1192_CR193","unstructured":"Cao, L., et al., Title: Overcoming transgene expressed \u03b1-Gal A interference for detection of anti-\u03b1-Gal A 1 antibodies after gene therapy treatment for Fabry disease AAPS J, 2025. TBD."},{"key":"1192_CR194","unstructured":"EMA. Upstaza. eladocagene exuparvovec. 2022 [cited 2025 May 20]; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/upstaza. Accessed\u00a003 Dec 2025."},{"key":"1192_CR195","unstructured":"ClinicalTrials.gov. A study of smartflow magnetic resonance (MR) compatible ventricular cannula for administering eladocagene exuparvovec to pediatric participants. NCT04903288. [cited 2025 May 10]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT04903288?term=NCT04903288&rank=1. Accessed\u00a003 Dec 2025."},{"key":"#cr-split#-1192_CR196.1","unstructured":"clinicaltrialsregister.eu. A Phase I\/II Clinical Trial for Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC. 2019 [cited 2025 May 11]"},{"key":"#cr-split#-1192_CR196.2","unstructured":"Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003032-23\/results. Accessed\u00a003 Dec 2025."},{"key":"#cr-split#-1192_CR197.1","unstructured":"clinicaltrialsregister.eu. A Clinical Trial for Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC - An Expansion. 2019 [cited 2025 May 11]"},{"key":"#cr-split#-1192_CR197.2","unstructured":"Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-003072-39\/results. Accessed\u00a003 Dec 2025."},{"key":"1192_CR198","unstructured":"EMA. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. 2018 [cited 2025 May 11]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-non-clinical-and-clinical-aspects-gene-therapy-medicinal-products_en.pdf. Accessed\u00a003 Dec 2025."},{"key":"1192_CR199","unstructured":"FDA. Preclinical Assessment of Investigational Cellular and Gene Therapy Products. Guidance for Industry. 2013 [cited 2025 May 11]; Available from: https:\/\/www.fda.gov\/media\/87564\/download. Accessed\u00a003 Dec 2025."},{"issue":"1\u20132","key":"1192_CR200","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41434-023-00417-x","volume":"31","author":"M Singh","year":"2024","unstructured":"Singh M, et al. Selection of appropriate non-clinical animal models to ensure translatability of novel AAV-gene therapies to the clinic. Gene Ther. 2024;31(1\u20132):56\u201363.","journal-title":"Gene Ther"},{"key":"1192_CR201","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","volume":"17","author":"AT Martino","year":"2020","unstructured":"Martino AT, Markusic DM. Immune response mechanisms against AAV vectors in animal models. Mol Ther Methods Clin Dev. 2020;17:198\u2013208.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"1192_CR202","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.yrtph.2009.03.012","volume":"54","author":"R Ponce","year":"2009","unstructured":"Ponce R, et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol. 2009;54(2):164\u201382.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1192_CR203","doi-asserted-by":"publisher","first-page":"1345473","DOI":"10.3389\/fimmu.2024.1345473","volume":"15","author":"MA Kroenke","year":"2024","unstructured":"Kroenke MA, et al. Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1\/IL-21 mutein fusion protein. Front Immunol. 2024;15:1345473.","journal-title":"Front Immunol"},{"key":"1192_CR204","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2019.103997","volume":"346","author":"SN Ashley","year":"2019","unstructured":"Ashley SN, et al. TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy. Cell Immunol. 2019;346:103997.","journal-title":"Cell Immunol"},{"key":"1192_CR205","first-page":"660","volume":"20","author":"G Gernoux","year":"2021","unstructured":"Gernoux G, et al. AAV8 locoregional delivery induces long-term expression of an immunogenic transgene in macaques despite persisting local inflammation. Mol Ther. 2021;20:660\u201374.","journal-title":"Mol Ther"},{"issue":"7","key":"1192_CR206","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1089\/hum.2018.234","volume":"30","author":"M Guilbaud","year":"2019","unstructured":"Guilbaud M, et al. Five years of successful inducible transgene expression following locoregional adeno-associated virus delivery in nonhuman primates with no detectable immunity. Hum Gene Ther. 2019;30(7):802\u201313.","journal-title":"Hum Gene Ther"},{"key":"1192_CR207","first-page":"279","volume":"22","author":"PO Ilyinskii","year":"2021","unstructured":"Ilyinskii PO, et al. Immtor nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia. Mol Ther. 2021;22:279\u201392.","journal-title":"Mol Ther"},{"issue":"6\u20137","key":"1192_CR208","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/jgm.2712","volume":"15","author":"A Majowicz","year":"2013","unstructured":"Majowicz A, et al. Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery. J Gene Med. 2013;15(6\u20137):219\u201332.","journal-title":"J Gene Med"},{"issue":"1","key":"1192_CR209","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/humc.2017.014","volume":"28","author":"JA Greig","year":"2017","unstructured":"Greig JA, et al. Non-clinical study examining AAV8.TBG.hLDLR vector-associated toxicity in chow-fed wild-type and LDLR(+\/-) rhesus macaques. Hum Gene Ther Clin Dev. 2017;28(1):39\u201350.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"1192_CR210","doi-asserted-by":"publisher","first-page":"1094279","DOI":"10.3389\/fimmu.2023.1094279","volume":"14","author":"J Hordeaux","year":"2023","unstructured":"Hordeaux J, et al. Immune transgene-dependent myocarditis in macaques after systemic administration of adeno-associated virus expressing human acid alpha-glucosidase. Front Immunol. 2023;14:1094279.","journal-title":"Front Immunol"},{"issue":"8","key":"1192_CR211","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe SW, et al. Gene therapy with Etranacogene Dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706\u201318.","journal-title":"N Engl J Med"},{"key":"1192_CR212","unstructured":"FDA. Human Gene Therapy for Rare Diseases. Guidance for Industry. 2020 [cited 2025 May 11]; Available from: https:\/\/www.fda.gov\/media\/113807\/download. Accessed\u00a003 Dec 2025."},{"key":"1192_CR213","unstructured":"FDA. In Vitro Companion Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff. 2014 [cited 2025 May 11]; Available from: https:\/\/www.fda.gov\/media\/81309\/download. Accessed\u00a003 Dec 2025."},{"key":"1192_CR214","unstructured":"EUR-Lex. Document 02017R0746\u201320250110. Consolidated text: Regulation (EU) 2017\/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98\/79\/EC and Commission Decision 2010\/227\/EU. 2017 [cited 2025 May 16]; Available from: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A02017R0746-20250110. Accessed\u00a003 Dec 2025."},{"key":"1192_CR215","unstructured":"FDA. Long Term Follow-up After Administration of Human Gene Therapy Products. Guidance for Industry. 2020 [cited 2025 May 11]; Available from: https:\/\/www.fda.gov\/media\/113768\/download. Accessed\u00a003 Dec 2025."},{"key":"1192_CR216","unstructured":"FDA. Human Gene Therapy for Hemophilia. Guidance for Industry. 2020 [cited 2025 May 11]; Available from: https:\/\/www.fda.gov\/media\/113799\/download. Accessed\u00a003 Dec 2025."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01192-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01192-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01192-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:02:33Z","timestamp":1770832953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01192-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":219,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01192-w","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are employed by and receive compensation from companies that are involved in development of gene therapy modality therapeutics which\u00a0are listed on the title page of the manuscript. The authors have no other relevant affiliations or financial involvements with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The views and conclusions presented in this paper are those of the authors and do not necessarily reflect the representative\u2019s affiliation or company\u2019s position on the subject.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"43"}}